First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-335 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection
Sponsor: Alios Biopharma Inc.
Listed as NCT02339207, this PHASE1 trial focuses on Chronic Hepatitis C and remains completed. Sponsored by Alios Biopharma Inc., it has been updated 8 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE1
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alios Biopharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .